Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2013

01-10-2013 | Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Current Insights and New Perspectives on the Roles of Hyperglucagonemia in Non-Insulin–Dependent Type 2 Diabetes

Authors: Xiao C. Li, Jia L. Zhuo

Published in: Current Hypertension Reports | Issue 5/2013

Login to get access

Abstract

Type 2 diabetes is well recognized as a noninsulin-dependent diabetic disease. Clinical evidence indicates that the level of circulating insulin may be normal, subnormal, and even elevated in type 2 diabetic patients. Unlike type 1 diabetes, the key problem for type 2 diabetes is not due to the absolute deficiency of insulin secretion, but because the body is no longer sensitive to insulin. Thus, insulin resistance is increased and the sensitivity to insulin is reset, so increasing levels of insulin are required to maintain body glucose and metabolic homeostasis. How insulin resistance is increased and what factors contribute to its development in type 2 diabetes remain incompletely understood. Overemphasis of insulin deficiency alone may be too simplistic for us to understand how type 2 diabetes is developed and should be treated, since glucose metabolism and homeostasis are tightly controlled by both insulin and glucagon. Insulin acts as a YIN factor to lower blood glucose level by increasing cellular glucose uptake, whereas glucagon acts as a YANG factor to counter the action of insulin by increasing glucose production. Furthermore, other humoral factors other than insulin and glucagon may also directly or indirectly contribute to increased insulin resistance and the development of hyperglycemia. The purpose of this article is to briefly review recently published animal and human studies in this field, and provide new insights and perspectives on recent debates as to whether hyperglucagonemia and/or glucagon receptors should be targeted to treat insulin resistance and target organ injury in type 2 diabetes.
Literature
1.
Matthaei S, Stumvoll M, Kellerer M, Haring H-U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000;21:585–618.PubMedCrossRef
2.
Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. [Review] [412 refs]. Pharmacol Rev. 2003;55(1):167–94.PubMedCrossRef
3.
•• Cryer PE. Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–48. This is a comprehensive review on interactions between pancreatic islet alpha-cell glucagon secretion and islet beta-cell insulin secretion. The author argues that in absolute endogenous insulin deficiency (i.e. in type 1 diabetes and in advanced type 2 diabetes), beta-cell failure results in no decrease in beta-cell insulin secretion, and thus no increase in alpha-cell glucagon secretion during hypoglycemia. However, the author also recognizes the increasing evidence that relative hyperglucagonemia, in the setting of deficient insulin secretion, plays a role in the pathogenesis of hyperglycemia in diabetes.PubMedCrossRef
4.
Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284(4):E671–8.PubMed
5.
•• Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122(1):4–12. The primary author is a well-recognized pioneer who advocated for the potential of targeting glucagon and/or GCGRs in the treatment of type 2 diabetes as early as in the 1970s. This is one of best overview articles summarizing the important role of the hormone glucagon in the pathogenesis of type 1 and type 2 diabetes. The authors provide the strong evidence and arguments for targeting glucagon and GCGRs in diabetes, and conclude that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.PubMedCrossRef
6.
•• Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(3):E415–21. This is a constructive article to review glucagon actions in hepatic and extrahepatic tissues, and provide the arguments for and against the concept of targeting Gcgr signaling for the treatment of T2DM.PubMedCrossRef
7.
Unger RH. Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA. 2008;299(10):1185–7.PubMedCrossRef
8.
Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004;113(11):1571–81.PubMed
9.
Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004;53:410–7.PubMedCrossRef
10.
Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A. 2003;100(3):1438–43.PubMedCrossRef
11.
•• Gelling RW, Vuguin PM, Du XQ, Cui L, Romer J, Pederson RA, et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab. 2009;297(3):E695–707. This study investigated the role of glucagon in the regulation of insulin secretion and whole body glucose homeostasis in vivo by generating mice overexpressing the Gcgr specifically on pancreatic beta-cells (RIP-Gcgr). The authors demonstrated that increased pancreatic beta-cell expression of the Gcgr increased insulin secretion, pancreatic insulin content, beta-cell mass, and, when mice were fed a HFD, partially protected against hyperglycemia and IGT.PubMedCrossRef
12.
Sorensen H, Winzell MS, Brand CL, Fosgerau K, Gelling RW, Nishimura E, et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes. 2006;55(12):3463–9.PubMedCrossRef
13.
Vuguin PM, Kedees MH, Cui L, Guz Y, Gelling RW, Nejathaim M, et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology. 2006;147(9):3995–4006.PubMedCrossRef
14.
Li XC, Liao TD, Zhuo JL. Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of type 2 diabetes in mice. Clin Sci (Lond). 2008;114(9):591–601.CrossRef
15.
•• Lee Y, Berglund ED, Wang MY, Fu X, Yu X, Charron MJ, et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A. 2012;109(37):14972–6. This study tested whether suppression of glucagon action will eliminate manifestations of diabetes by expressing GCGRs in livers of glucagon receptor-null (GcgR(−/−)) mice before and after beta-cell destruction by high-dose streptozotocin. The authors conclude from their results that the metabolic manifestations of diabetes cannot occur without glucagon action and, once present, disappear promptly when glucagon action is abolished. The study supports the notion that glucagon suppression should be a major therapeutic goal in diabetes.PubMedCrossRef
16.
• Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011;60(2):391–7. In this article, the authors compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr(−/−)) mice and wild-type (Gcgr(+/+)) controls after equivalent destruction of beta-cells with streptozotocin. The study shows striking results that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.PubMedCrossRef
17.
• Ramanathan RP, Arbelaez AM, Cryer PE. Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia. Diabetes. 2011;60(4):1324–8. This study tested the hypotheses that in nondiabetic individuals, partial inhibition of insulin secretion with the ATP-sensitive K(+) channel agonist (opener) diazoxide induces hyperglycemia and hyperglucagonemia after a mixed meal and after administration of the sulfonylurea glimepiride. The results show that partial inhibition of insulin secretion results in impairment of glucose tolerance after a mixed meal and after glimepiride administration in the absence of glucagon secretion. The study suggests that beta-cell secretion is not the only regulator of alpha-cell glucagon secretion.PubMedCrossRef
18.
Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia. 2007;50(1):142–50.PubMedCrossRef
19.
Unson CG, Gurzenda EM, Merrifield RB. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides. 1989;10:1171–7.PubMedCrossRef
20.
Buggy JJ, Heurich RO, MacDougall M, Kelley KA, Livington JN, Yoo-Warren H, et al. Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization. Diabetes. 1997;46:1400–5.PubMedCrossRef
21.
Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001;44:2018–24.PubMedCrossRef
22.
Bromer WW, Sinn LG, Staub A, Behrens OK. The amino acid sequence of glucagon. J Am Chem Soc. 1956;78:3858–9.CrossRef
23.
Baum J, Simon BF, Unger RH, Madison LL. Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent techniques. Diabetes. 1962;11:371–4.PubMed
24.
Villanueva ML, Hedo JA, Marco J. Plasma glucagon immunoreactivity in a totally pancreatectomized patient. Diabetologia. 1976;12(6):613–6.PubMedCrossRef
25.
Werner PL, Palmer JP. Immunoreactive glucagon responses to oral glucose, insulin infusion and deprivation, and somatostatin in pancreatectomized man. Diabetes. 1978;27(10):1005–12.PubMedCrossRef
26.
Hatton TW, Yip CC, Vranic M. Biosynthesis of glucagon (IRG3500) in canine gastric mucosa. Diabetes. 1985;34(1):38–46.PubMedCrossRef
27.
Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. PNAS. 1982;79:345–9.PubMedCrossRef
28.
Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, et al. Expression cloning and signaling properties of the rat glucagon receptor. Science. 1993;259:1614–6.PubMedCrossRef
29.
Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, et al. The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994;140:203–9.PubMedCrossRef
30.
Butlen D, Morel F. Glucagon receptors along the nephron: [125I]glucagon binding in rat tubules. Pflugers Arch. 1985;404:348–53.PubMedCrossRef
31.
Marks J, Debnam ES, Dashwood MR, Srai SK, Unwin RJ. Detection of glucagon receptor mRNA in the rat proximal tubule: potential role for glucagon in the control of renal glucose transport. Clin Sci (Lond). 2003;104:253–8.CrossRef
32.
Rodbell M, Birnbaumer L, Pohl SL, Krans HM. The glucagon-sensitive adenylyl cyclase system in plasma membranes of rat liver. V. an obligatory role of guanylnucleotides in glucagon action. J Biol Chem. 1971;246:1877–82.PubMed
33.
Wakelam MJ, Murphy GJ, Hruby VJ, Houslay MD. Activation of two signal-transduction systems in hepatocytes by glucagon. Nature (Lond). 1986;323:68–71.CrossRef
34.
Li XC, Carretero OA, Zhuo JL. Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells. Biochem Pharmacol. 2006;71(12):1711–9.PubMedCrossRef
35.
Li XC, Carretero OA, Shao Y, Zhuo JL. Glucagon receptor-mediated ERK 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hypertension. 2006;47:1–6.CrossRef
36.
•• Vuguin PM, Charron MJ. Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes Metab. 2011;13 Suppl 1:144–50. This review article provides an overview on genetically modified animal models of glucagon signalling in metabolism. The authors summarize evidence that mice with a global deletion of the glucagon receptor gene (Gcgr) may be associated with poor fetal growth, altered cytoarchitecture of pancreatic islets and glucose, lipid and hormonal profiles; altered body composition and protection from diet-induced obesity; impaired hepatocyte survival; altered metabolic response to prolonged fasting and exercise, and prevention of development of diabetes in insulin-deficient mice. The authors caution that blockage of Gcgr activation may have negative implications in the treatment of diabetes.PubMedCrossRef
37.
• Maharaj A, Zhu L, Huang F, Qiu H, Li H, Zhang CY, et al. Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes. Diabetologia. 2012;55(5):1458–68. In this study, the investigators generated transgenic mice in which the expression of Gcgr is driven by the muscle specific creatine kinase (Mck) promoter, and assessed the effects of glucagon on the modulation of glucose homeostasis under conditions of extremes of glucose influx or efflux. The results suggest that mild and chronic hyperglucagonaemia provides beneficial effects on beta cell function and glucose homeostasis.PubMedCrossRef
38.
Li XC, Zhuo JL. Targeting glucagon receptor signaling in treating metabolic syndrome and renal injury in type 2 diabetes: theory versus promise. Clin Sci. 2007;113:183–93.PubMedCrossRef
39.
Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab. 2008;295:E751–61.PubMedCrossRef
40.
Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;4:14–6.CrossRef
41.
Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism. 1978;27(11):1691–709.PubMedCrossRef
42.
Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia. 1985;28(8):574–8.PubMedCrossRef
43.
Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia through the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64:106–10.PubMedCrossRef
44.
Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991;87:415–23.PubMedCrossRef
45.
Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes. 2006;55(8):2318–23.PubMedCrossRef
46.
• Jamison RA, Stark R, Dong J, Yonemitsu S, Zhang D, Shulman GI, et al. Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am J Physiol Endocrinol Metab. 2011;301(6):E1174–83. In this study, the investigators infused glucaose in normal awake rats continuously for 10 days to induce hyperglycemia and determine its impact on markers of islet and liver function. Although rats adapted initially to hyperglycemia, and maintained euglycemia for approximately 4 days, continued infusion of glucose led to worsening hyperglycemia in 89 % of rats after 10 days. Plasma insulin and C-peptide concentrations remained largely unchanged, whereas plasma glucagon concentrations increased five-fold. These data support the novel concept that hyperglycemia may paradoxically increase glucagon secretion in type 2 diabetic patients.PubMedCrossRef
47.
Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053–9.PubMedCrossRef
48.
Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol. 1999;277(2 Pt 1):E283–90.PubMed
49.
Webb GC, Akbar MS, Zhao C, Swift HH, Steiner DF. Glucagon replacement via micro-osmotic minipump corrects hypoglycemia and [alpha]-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes. 2002;51:398–405.PubMedCrossRef
50.
Harris PJ, Skinner SL, Zhuo JL. The effects of atrial natriuretic peptide and glucagon on proximal glomerulotubular balance in anesthetized rats. J Physiol (Lond). 1988;402:29–42.
51.
Ahloulay M, Dechaux M, Hassler C, Bouby N, Bankir L. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J Clin Invest. 1996;98:2251–8.PubMedCrossRef
52.
53.
Breyer MD, Bottinger E, Brosius III FC, Coffman TM, Harris RC, Heilig CW, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27–45.PubMedCrossRef
54.
Gartner K. Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). Diabetologia. 1978;15:59–63.PubMedCrossRef
55.
Levine DZ, Iacovitti M, Robertson SJ, Mokhtar GA. Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2006;290:R975–81.PubMedCrossRef
56.
•• Engel SS, Xu L, Andryuk PJ, Davies MJ, Kaufman K, Goldstein BJ. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist, in patients with type 2 diabetes. Diabetes. 2011;60:A85. (Abstract). This is a moderate phase II, randomized study invoving 342 type 2 diabetic patients treated with once-daily administration of the GCGR antagonistt MK-0893 in four different dosages, metformin, or placebo. 12 week-treatment with MK-0893 caused significant, dose-dependent reductions in fasting and postprandial plasma glucose, and HbA1c, compared with placebo. Low incidences of hypoglycemia were observed in all groups. This study provides clinical evidence that GCGRs ma be targeted for the treatment of type 2 diabetes in humans.
57.
•• Kelly RP, Garhyan P, Abu-Raddad EJ, Lim CN, Prince MJ, Pinaire JA, et al. Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose and HbA1c in patients with type 2 diabetes mellitus. Diabetes. 2011;60:A84. (Abstract). This is a small Phase 1, randomized, double-blind, placebo (PBO)-controlled study that evaluated the safety, tolerability, pharmacokinetics, and short-term (4 weeks) efficacy of once-daily doses of GCGR antagonist LY2409021 (5, 30, 60, or 90 mg) in patients with T2DM treated with diet and exercise or metformin (N = 47). LY2409021 significantly reduced fasting blood glucose by Day 14 by >30 mg/dL in 5 of 9 patients in the 90 mg dose group, with no clinical signs or significant elevations in bilirubin or alkaline phosphatase. Thus, this study supports the concept that glucagon receptor antagonists may be developed for the treatment of T2DM.
58.
Sorensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes. 2006;55(10):2843–8.PubMedCrossRef
59.
• Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009;331(3):871–81. This study demonstrates that a 5-week treatment of diet-induced obese mice with mAb effectively normalized nonfasting blood glucose, reduced fasting blood glucose without inducing hypoglycemia or other undesirable metabolic perturbations. In addition, no hypoglycemia was found in db/db mice that were treated with a combination of insulin and mAb.PubMedCrossRef
Metadata
Title
Current Insights and New Perspectives on the Roles of Hyperglucagonemia in Non-Insulin–Dependent Type 2 Diabetes
Authors
Xiao C. Li
Jia L. Zhuo
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 5/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0383-y

Other articles of this Issue 5/2013

Current Hypertension Reports 5/2013 Go to the issue

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Hypertension after Kidney Transplantation: A Pathophysiologic Approach

Pediatric Hypertension (JT Flynn, Section Editor)

Determinants of Neonatal Blood Pressure

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

Pediatric Hypertension (JT Flynn, Section Editor)

Primary Hypertension in Childhood

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits